| 000 | 01588 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250516055107.0 | ||
| 264 | 0 | _c20120709 | |
| 008 | 201207s 0 0 eng d | ||
| 022 | _a1437-7799 | ||
| 024 | 7 |
_a10.1007/s10157-011-0533-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTomino, Yasuhiko | |
| 245 | 0 | 0 |
_aMechanisms and interventions in peritoneal fibrosis. _h[electronic resource] |
| 260 |
_bClinical and experimental nephrology _cFeb 2012 |
||
| 300 |
_a109-14 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAngiotensin Receptor Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aEpithelial Cells _xtransplantation |
| 650 | 0 | 4 |
_aEpithelium _xtransplantation |
| 650 | 0 | 4 |
_aGlycation End Products, Advanced _xadverse effects |
| 650 | 0 | 4 |
_aGuanidines _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xtherapy |
| 650 | 0 | 4 |
_aPeritoneal Dialysis _xadverse effects |
| 650 | 0 | 4 |
_aPeritoneal Fibrosis _xdrug therapy |
| 650 | 0 | 4 |
_aPeritoneum _xpathology |
| 650 | 0 | 4 |
_aPhenyl Ethers _xtherapeutic use |
| 650 | 0 | 4 |
_aPyridoxamine _xtherapeutic use |
| 650 | 0 | 4 |
_aRenin-Angiotensin System _xdrug effects |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aortho-Aminobenzoates _xtherapeutic use |
| 773 | 0 |
_tClinical and experimental nephrology _gvol. 16 _gno. 1 _gp. 109-14 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10157-011-0533-y _zAvailable from publisher's website |
| 999 |
_c21173831 _d21173831 |
||